Alto Neuroscience, Inc. (NYSE:ANRO) Holdings Lowered by Bowie Capital Management LLC

Bowie Capital Management LLC lowered its stake in Alto Neuroscience, Inc. (NYSE:ANRO) by 54.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,484 shares of the company’s stock after selling 23,702 shares during the quarter. Alto Neuroscience makes up 0.0% of Bowie Capital Management LLC’s investment portfolio, making the stock its 29th largest holding. Bowie Capital Management LLC owned about 0.07% of Alto Neuroscience worth $223,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Rhumbline Advisers acquired a new position in shares of Alto Neuroscience during the 2nd quarter valued at about $113,000. Federated Hermes Inc. grew its holdings in Alto Neuroscience by 33.3% during the second quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock valued at $128,000 after purchasing an additional 3,000 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Alto Neuroscience in the second quarter valued at approximately $252,000. TD Asset Management Inc acquired a new stake in shares of Alto Neuroscience in the second quarter worth $928,000. Finally, Zimmer Partners LP bought a new stake in shares of Alto Neuroscience during the 1st quarter worth $1,151,000.

Alto Neuroscience Stock Up 2.1 %

Shares of Alto Neuroscience stock traded up $0.09 during trading on Monday, hitting $4.40. 17,941 shares of the company’s stock traded hands, compared to its average volume of 374,026. Alto Neuroscience, Inc. has a twelve month low of $3.61 and a twelve month high of $24.00. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09. The firm’s fifty day moving average price is $8.77 and its 200 day moving average price is $10.92.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.05. As a group, equities analysts anticipate that Alto Neuroscience, Inc. will post -2.54 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. William Blair reiterated an “outperform” rating on shares of Alto Neuroscience in a report on Tuesday, September 10th. Robert W. Baird decreased their target price on Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Rodman & Renshaw lowered Alto Neuroscience from a “buy” rating to a “neutral” rating in a report on Wednesday, October 23rd. RODMAN&RENSHAW lowered Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Finally, Wedbush downgraded shares of Alto Neuroscience from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $29.00 to $4.00 in a research note on Wednesday, October 23rd. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Alto Neuroscience presently has an average rating of “Moderate Buy” and an average target price of $20.00.

Alto Neuroscience Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.